Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases. 

Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participated in the round.  

The company is building an AI imaging laboratory to house Qureight’s 3D chest imaging Foundation Model, significantly reducing both the data requirement and the time needed to develop new disease models. This will allow Qureight to bring new products to market in new disease areas where there is high demand for advanced imaging analytics to improve clinical trial design: asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. The new disease models will complement Qureight’s existing models in lung fibrosis and expand the company’s market reach. To support this growth and meet demand for its imaging CRO services, the funding will also allow Qureight to scale its commercial team.  

In addition, the funding will enable the development of Qureight’s AI-powered quantitative imaging analytics platform to further improve the speed and design of clinical trials. Qureight’s services are already being utilised by biopharma partners, providing real-time insights and precision endpoints to accelerate clinical trials in a number of fibrotic lung diseases. 

“The global lung and heart clinical trials market is expected to grow to $27.5bn by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials,” said Dr Muhunthan Thillai, Co-Founder and CEO, Qureight.